Supplemental Data from A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
Year: 2023
Type: supplementary-materials
Abstract: Methodology and results for exploratory aims, FISH, IHC and quality of life. SUPPLEMENTAL FIGURE 1: Change point analysis including a second inflection point in calculation of average slope of 34 evaluable patients. Supplemental Figure 2: First, last, and difference between first and last measurements for Fact-G and its components. Supplemental Figure 3: QOL trajectory for each patient by FACT-G analysis. Supplemental table 1: Mutation analysis as provided by Foundation Medicine for a subset of patients with residual tissue available for targeted mutation profiling. Table 2: Basic statistics for first, last, and difference between first and last measurements of Fact-G and its components Supplemental Figure 3: QOL trajectory for each patient by FACT-G analysis. Supplemental Table 3: Summary of adverse event counts for all consented patients. Supplemental Table 4: PET response at day 12 PET scan compared with baseline PET scans.
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361969443